Centre may bring 16 common drugs for cough, cold, pain under OTC category

A gazette notification seeking suggestions from stakeholders within a month over the matter has been issued by the ministry.

pharmacy, drugs, medicine, pharma companies, pharmaceuticals
The Union Health Ministry has suggested amendments to the Drugs Rules, 1945, to bring 16 such medicines under Schedule K for providing exemptions from requiring a doctor's prescription so that they can be sold over-the-counter by retail sellers under
Press Trust of India New Delhi
1 min read Last Updated : Jun 07 2022 | 10:33 PM IST

Commonly used drugs for cough, cold, pain and skin irritation such as paracetamol, nasal decongestants and antifungals may soon be available without prescription as the Centre plans to list them under the over-the-counter (OTC) category.

The Union Health Ministry has suggested amendments to the Drugs Rules, 1945, to bring 16 such medicines under Schedule K for providing exemptions from requiring a doctor's prescription so that they can be sold over-the-counter by retail sellers under a valid license.

A gazette notification seeking suggestions from stakeholders within a month over the matter has been issued by the ministry.

Those 16 medicines include Povidone Iodine, an antiseptic and disinfectant agent; Chlorohexidine mouthwash for gingivitis, Clotrimazole an antifungal cream; Dextromethorphan Hydrobromide lozenges for cough; analgesic ointment Diclofenac; Benzoyl peroxide which is an antibacterial for acne; Diphenhydramine capsules, an antihistaminic and antiallergic drug; Paracetamol; some nasal decongestants and laxatives.

Once the proposal is cleared, these drugs can be sold in retail OTC without doctors' prescription with certain riders such as the maximum duration of treatment should not exceed five days and if the symptoms do not resolve the patient should consult a doctor.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :drugsHealth Ministry

First Published: Jun 07 2022 | 5:24 PM IST

Next Story